Bailard Inc. Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bailard Inc. increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,422 shares of the biopharmaceutical company’s stock after purchasing an additional 1,236 shares during the period. Bailard Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,561,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. State Street Corp grew its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after purchasing an additional 11,499 shares during the period. Swiss National Bank grew its position in shares of Regeneron Pharmaceuticals by 0.6% in the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after purchasing an additional 2,000 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after acquiring an additional 1,108 shares during the last quarter. Finally, National Pension Service boosted its holdings in Regeneron Pharmaceuticals by 4.0% in the fourth quarter. National Pension Service now owns 232,450 shares of the biopharmaceutical company’s stock valued at $165,581,000 after acquiring an additional 8,833 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ REGN opened at $698.74 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The firm has a market cap of $76.39 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock’s 50-day simple moving average is $698.51 and its 200-day simple moving average is $868.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $11.86 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on REGN. Oppenheimer reduced their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Robert W. Baird reduced their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Finally, Citigroup reduced their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.